The study targeted six biomarkers, including well-established ones like EGFR, p53, and Ki67 used in clinical diagnostics, alongside newer markers such as PD-L1, HLA-E, and B7-H6, which are pertinent to the tumor microenvironment and mechanisms of immune evasion. Here, MKI67 is linked to neoplasm.